Abstract:Purpose(:) To evaluate the pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in diagnosing and staging liver fibrosis in rabbits.Materials and Methods: DCE-MRI with gadodiamide (Gd-DTPA-BMA) was performed on a 3.0 Tesla, 60cm bore MR scanner for rabbits with CCl4-induced liver fibrosis, and an untreated control group. Fibrosis was staged according to the METAVIR system: control (F0; n=13), nonadvanced fibrosis (F1-2; n=15), and advanced fibrosis (F3-4; n=12). The DCE-MRI parameters K-trans, k(ep), V-e, and v(p) were measured with a dual-input extended Tofts model. Receiver operating characteristic analyses were performed to assess the diagnostic performance of K-trans, V-e, and v(p) in staging liver fibrosis.Results: Both K-trans and V-e decreased with increasing fibrosis stage. K-trans of the control group was significantly different from that of the overall fibrosis group, nonadvanced group, and advanced group (P < 0.001 for all). Significant differences were found between V-e of the control group and that of the overall fibrosis and advanced groups (P=0.019 and P=0.009, respectively). For K-trans, the areas under the receiver operating characteristic curve (AUROCs) for discriminating the control group from the overall fibrosis and advanced fibrosis groups were 0.909 (95% confidence interval [CI], 0.809-1.000), and 0.936 (95% CI, 0.847-1.000), respectively. For discriminating between the control and nonadvanced fibrosis groups, the AUROC of K-trans was 0.887 (95% CI, 0.762-1.000). The AUROCs of K-trans were higher than those of V-e and v(p) for discriminating between the control and overall fibrosis groups, the control and nonadvanced fibrosis groups, and the control and advanced fibrosis groups. Pharmacokinetic parameters were negatively correlated with fibrosis stage (K-trans, rho=-0.668, P < 0.001; V-e, rho=-0.438, P=0.005; v(p), rho=-0.360, P=0.023).Conclusion: Among pharmacokinetic parameters of DCE-MRI in our study, K-trans was an excellent predictor for differentiating fibrotic livers from normal livers, and differentiating normal livers from nonadvanced or advanced fibrosis livers.

Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ3 for staging liver fibrosis in rat model

Molecular Magnetic Resonance Imaging of Activated Hepatic Stellate Cells with Ultrasmall Superparamagnetic Iron Oxide Targeting Integrin αvβ3 for Staging Liver Fibrosis in Rat Model

Molecular Imaging of Hepatic Stellate Cell Activity by Visualization of Hepatic Integrin Αvβ3 Expression with SPECT in Rat

Enhanced US/CT/MR imaging of integrin αvβ3 for liver fibrosis staging in rat

MR Imaging of Activated Hepatic Stellate Cells in Liver Injured by CCl 4 of Rats with Integrin-Targeted Ultrasmall Superparamagnetic Iron Oxide

Integrin-Targeted Theranostic Nanoparticles for Clinical MRI-Traceable Treatment of Liver Fibrosis

Liver injury monitoring, fibrosis staging and inflammation grading using T1rho magnetic resonance imaging: an experimental study in rats with carbon tetrachloride intoxication

Non-invasively Differentiating Extent of Liver Fibrosis by Visualizing Hepatic Integrin Αvβ3 Expression with an MRI Modality in Mice

Ultrasound molecular imaging with cRGD-PLGA-PFOB nanoparticles for liver fibrosis staging in a rat model.

Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin Αvβ3-Targeting Radiotracer.

T 1-T2 Dual-Modal Magnetic Resonance Contrast-Enhanced Imaging for Rat Liver Fibrosis Stage

Therapeutic Effect and Location of GFP-Labeled Placental Mesenchymal Stem Cells on Hepatic Fibrosis in Rats

Assessment and integration of multiparametric MRI for liver fibrosis staging in rat non-alcoholic steatohepatitis: Evaluation of diagnostic efficiency and model interpretation

The hepatocyte phase of Gd-EOB-DTPA-enhanced MRI in the evaluation of hepatic fibrosis and early liver cirrhosis in a rat model: An experimental study

Assessment of Liver Fibrosis Using Pharmacokinetic Parameters of Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Non-invasively Differentiate Non-Alcoholic Steatohepatitis by Visualizing Hepatic Integrin Αvβ3 Expression with a Targeted Molecular Imaging Modality

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Staging of Liver Fibrosis Treated with Hepatocyte Growth Factor by Ultrasound Cationic Microbubble Nano-Liposomes Using 1H Magnetic Resonance Spectroscopy

Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Gd-Eob-Dtpa for the Evaluation of Liver Fibrosis Induced by Carbon Tetrachloride in Rats

Study On The In Vitro And In Vivo Activation Of Rat Hepatic Stellate Cells By Raman Spectroscopy (Vol 12, Art No 034003, 2007)